S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.69 (+1.52%)
AAPL   179.66 (-0.60%)
MSFT   415.32 (+0.41%)
META   502.27 (+2.48%)
GOOGL   137.06 (-1.01%)
AMZN   178.32 (+0.88%)
TSLA   202.65 (+0.38%)
NVDA   821.80 (+3.88%)
NIO   5.78 (+0.52%)
AMD   202.33 (+5.09%)
BABA   74.64 (+0.82%)
T   17.00 (+0.41%)
F   12.44 (+0.00%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.71 (+1.16%)
DIS   111.99 (+0.37%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.53 (+0.31%)
XOM   105.75 (+1.18%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.69 (+1.52%)
AAPL   179.66 (-0.60%)
MSFT   415.32 (+0.41%)
META   502.27 (+2.48%)
GOOGL   137.06 (-1.01%)
AMZN   178.32 (+0.88%)
TSLA   202.65 (+0.38%)
NVDA   821.80 (+3.88%)
NIO   5.78 (+0.52%)
AMD   202.33 (+5.09%)
BABA   74.64 (+0.82%)
T   17.00 (+0.41%)
F   12.44 (+0.00%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.71 (+1.16%)
DIS   111.99 (+0.37%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.53 (+0.31%)
XOM   105.75 (+1.18%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.69 (+1.52%)
AAPL   179.66 (-0.60%)
MSFT   415.32 (+0.41%)
META   502.27 (+2.48%)
GOOGL   137.06 (-1.01%)
AMZN   178.32 (+0.88%)
TSLA   202.65 (+0.38%)
NVDA   821.80 (+3.88%)
NIO   5.78 (+0.52%)
AMD   202.33 (+5.09%)
BABA   74.64 (+0.82%)
T   17.00 (+0.41%)
F   12.44 (+0.00%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.71 (+1.16%)
DIS   111.99 (+0.37%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.53 (+0.31%)
XOM   105.75 (+1.18%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.69 (+1.52%)
AAPL   179.66 (-0.60%)
MSFT   415.32 (+0.41%)
META   502.27 (+2.48%)
GOOGL   137.06 (-1.01%)
AMZN   178.32 (+0.88%)
TSLA   202.65 (+0.38%)
NVDA   821.80 (+3.88%)
NIO   5.78 (+0.52%)
AMD   202.33 (+5.09%)
BABA   74.64 (+0.82%)
T   17.00 (+0.41%)
F   12.44 (+0.00%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.71 (+1.16%)
DIS   111.99 (+0.37%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.53 (+0.31%)
XOM   105.75 (+1.18%)
NASDAQ:LPCN

Lipocine (LPCN) Stock Price, News & Analysis

$3.83
+0.02 (+0.52%)
(As of 02:37 PM ET)
Today's Range
$3.77
$4.00
50-Day Range
$2.79
$4.11
52-Week Range
$2.31
$8.16
Volume
8,130 shs
Average Volume
27,802 shs
Market Capitalization
$20.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
LPCN stock logo

About Lipocine Stock (NASDAQ:LPCN)

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

LPCN Stock Price History

LPCN Stock News Headlines

StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)
Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
Lipocine Signs TLANDO Franchise License Deal With Verity Pharma
Lipocine to Present at Biotech Showcase 2024
Lipocine files for $150M mixed shelf
Lipocine Inc LPCN
LPCN: Trial Results Improve Outlook
LPCN: 1148 Shows Muscle Loss Reversal
Why Lipocine Stock Is Moving Higher Today?
See More Headlines
Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/10/2023
Today
3/01/2024
Next Earnings (Estimated)
3/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LPCN
Employees
17
Year Founded
1997

Profitability

Net Income
$-10,760,000.00
Pretax Margin
-21,921.82%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Book Value
$6.85 per share

Miscellaneous

Free Float
5,050,000
Market Cap
$20.75 million
Optionable
No Data
Beta
1.05

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Mahesh V. Patel Ph.D. (Age 67)
    Co-Founder, Interim Principal Financial Officer, Director, President & CEO
    Comp: $598.91k
  • Ms. Krista Fogarty (Age 56)
    Principal Accounting Officer & Corporate Controller
    Comp: $268.12k
  • Dr. Nachiappan Chidambaram Ph.D. (Age 54)
    Senior Vice President of Research & Development
    Comp: $311.17k
  • Mr. Logan Morse (Age 54)
    Vice President of Sales, Marketing & Operations
    Comp: $413.58k
  • Mr. Morgan R. Brown CPA (Age 56)
    M.B.A., Corporate Secretary
    Comp: $472.45k














LPCN Stock Analysis - Frequently Asked Questions

How have LPCN shares performed in 2024?

Lipocine's stock was trading at $2.79 at the start of the year. Since then, LPCN stock has increased by 39.8% and is now trading at $3.90.
View the best growth stocks for 2024 here
.

When is Lipocine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 8th 2024.
View our LPCN earnings forecast
.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) announced its earnings results on Friday, March, 10th. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter.

When did Lipocine's stock split?

Lipocine's stock reverse split on Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Lipocine own?
Who are Lipocine's major shareholders?

Lipocine's stock is owned by a variety of retail and institutional investors. Top institutional investors include Wealth Effects LLC (0.28%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Krista Fogarty, Mahesh V Patel, Richard Dana Ono and Spyros Papapetropoulos.
View institutional ownership trends
.

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LPCN) was last updated on 3/1/2024 by MarketBeat.com Staff

From Our Partners